Cardiorenal syndrome: Plasmonic biosensors

Area of Science:

• Biomedical Engineering
• Cardiology
• Nephrology

Background:

• Cardiorenal syndrome (CRS) involves heart and kidney dysfunction, leading to significant morbidity and mortality.
• Early diagnosis of CRS is crucial for timely intervention and improved patient prognosis.
• Neutrophil gelatinase-associated lipocalin (NGAL) and brain (B-type) natriuretic peptide (BNP) are key biomarkers for cardiac and kidney impairment.

Purpose of the Study:

• To review the application of Surface Plasmon Resonance (SPR) optical biosensors for detecting NGAL and BNP.
• To explore the potential of SPR technology in the early detection and management of CRS.
• To discuss the implications of SPR-based diagnostics for improving treatment strategies and patient outcomes in CRS.

Main Methods:

• Review of existing literature on CRS biomarkers and SPR biosensor technology.
• Analysis of SPR's sensitivity and specificity for NGAL and BNP detection.
• Discussion of the integration of SPR biosensors into clinical practice for CRS management.

Main Results:

• NGAL and BNP are established biomarkers indicative of CRS.
• SPR biosensors offer a highly sensitive and specific method for detecting these biomarkers.
• SPR technology holds promise for rapid and accurate CRS diagnosis.

Conclusions:

• SPR biosensors represent a significant advancement for the early detection of cardiorenal syndrome.
• This technology can facilitate timely risk stratification and personalized treatment approaches.
• Implementing SPR-based detection can potentially reduce the high morbidity and mortality associated with CRS.